Table 1. Ongoing clinical trials.

Trail number	Institution	SBRT dose (Gy)/fraction	Target organs	Immunotherapy drug	Treatment order	Phase
NCT01950195	Johns Hopkins University	NS	Brain, spine	Ipilimumab	Immunotherapy, then SABR, then immunotherapy	I
NCT01497808	University of Pennsylvania	NS	NS	Ipilimumab	SABR then immunotherapy	I/II
NCT02239900	MD Anderson Cancer Center	50/4 or 60/10	Liver, lung, adrenal	Ipilimumab	Concurrent; or immunotherapy then SABR	I/II
NCT01862900	Chiles Research Institute	15/1 or 20/1	Lung, liver	Anti-OX40	Concurrent	I/II
NCT01769222	Stanford University	20/2	Any	Ipilimumab	Concurrent	I/II
NCT01401062	New York University	22.5/3	Any	Fresolimumab	Concurrent	I/II
NCT02298946	NIH/NCI	8/1 or 24/3	Liver	PD-1 inhibitor	SABR then immunotherapy	I
NCT01703507	Thomas Jefferson University	24/1 or 21/1 or 18/1 or 15/1	Brain	Ipilimumab	Concurrent	I
NCT02444741	MD Anderson Cancer Center	50/4	Lung, liver	PD-1 inhibitor

NCI, National Cancer Institute; SBRT, stereotactic body radiotherapy; NS, not specified; PD-1, programmed cell death protein 1.